Clinical Trials Directory

Trials / Unknown

UnknownNCT00008749

Role of Altered CD40-Ligand Gene Transcription in Systemic Lupus Erythematosus

Status
Unknown
Phase
Study type
Observational
Enrollment
Sponsor
National Center for Research Resources (NCRR) · NIH
Sex
All
Age
13 Years
Healthy volunteers
Accepted

Summary

Systemic lupus erythematosus is an often devastating autoimmune disease which affects 1 in 2,000 women in the United States. Recently, several research laboratories have reported that a protein, named CD40-ligand (CD154), is overexpressed by a subset of white blood cells, called lymphocytes, in patients with lupus. Expression of CD154 appears critical to the generation of antibodies that cause disease in lupus. Blocking CD154 interactions in the immune system has been shown to decrease disease activity in animal models of lupus. We propose to study the regulation of CD154 in patients with lupus in hopes of inhibiting its abnormal and deleterious expression.

Conditions

Timeline

First posted
2001-01-18
Last updated
2005-06-24

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00008749. Inclusion in this directory is not an endorsement.